Literature DB >> 33288638

Alkoxylalkyl Esters of Nucleotide Analogs Inhibit Polyomavirus DNA Replication and Large T Antigen Activities.

Nichodemus O Onwubiko1, Suraya A Diaz1, Marcela Krečmerová2, Heinz Peter Nasheuer3.   

Abstract

Polyomavirus infections occur commonly in humans and are normally nonfatal. However, in immunocompromised individuals, they are intractable and frequently fatal. Due to a lack of approved drugs to treat polyomavirus infections, cidofovir, a phosphonate nucleotide analog approved to treat cytomegalovirus infections, has been repurposed as an antipolyomavirus agent. Cidofovir has been modified in various ways to improve its efficacies as a broad-spectrum antiviral agent. However, the actual mechanisms and targets of cidofovir and its modified derivatives as antipolyomavirus agents are still under research. Here, polyomavirus large tumor antigen (Tag) activities were identified as the viral target of cidofovir derivatives. The alkoxyalkyl ester derivatives of cidofovir efficiently inhibit polyomavirus DNA replication in cell-free human extracts and a viral in vitro replication system utilizing only purified proteins. We present evidence that DNA helicase and DNA binding activities of polyomavirus Tags are diminished in the presence of low concentrations of alkoxyalkyl ester derivatives of cidofovir, suggesting that the inhibition of viral DNA replication is at least in part mediated by inhibiting single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) binding activities of Tags. These findings show that the alkoxyalkyl ester derivatives of cidofovir are effective in vitro without undergoing further conversions, and we conclude that the inhibitory mechanisms of nucleotide analog-based drugs are more complex than previously believed.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  ATPase; DNA helicase; DNA replication; large T antigen; nucleoside analogs; polyomavirus; protein-DNA interactions

Mesh:

Substances:

Year:  2021        PMID: 33288638      PMCID: PMC8092500          DOI: 10.1128/AAC.01641-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  80 in total

1.  Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation.

Authors:  Benjamin Bridges; Sarah Donegan; Ashraf Badros
Journal:  Am J Hematol       Date:  2006-07       Impact factor: 10.047

2.  Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate.

Authors:  Wendy C Magee; Karl Y Hostetler; David H Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Eric A Coomes; Amanda Wolfe Jacques; Fotios V Michelis; Dennis Dong Hwan Kim; Santhosh Thyagu; Auro Viswabandya; Jeffrey H Lipton; Hans A Messner; Uday Deotare
Journal:  Biol Blood Marrow Transplant       Date:  2018-04-18       Impact factor: 5.742

4.  Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.

Authors:  Stephanie L Williams-Aziz; Caroll B Hartline; Emma A Harden; Shannon L Daily; Mark N Prichard; Nicole L Kushner; James R Beadle; W Brad Wan; Karl Y Hostetler; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.

Authors:  Earl R Kern; Caroll Hartline; Emma Harden; Kathy Keith; Natalie Rodriguez; James R Beadle; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

6.  Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN).

Authors:  H M Wadei; A D Rule; M Lewin; A S Mahale; H A Khamash; T R Schwab; J M Gloor; S C Textor; M E Fidler; D J Lager; T S Larson; M D Stegall; F G Cosio; M D Griffin
Journal:  Am J Transplant       Date:  2006-05       Impact factor: 8.086

7.  Synthesis of cidofovir and (S)-HPMPA ether lipid prodrugs.

Authors:  James R Beadle
Journal:  Curr Protoc Nucleic Acid Chem       Date:  2007-06

8.  Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy.

Authors:  Carlos E Araya; Judy F Lew; Robert S Fennell; Richard E Neiberger; Vikas R Dharnidharka
Journal:  Pediatr Transplant       Date:  2006-02

Review 9.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

10.  SV40 T antigen interactions with ssDNA and replication protein A: a regulatory role of T antigen monomers in lagging strand DNA replication.

Authors:  Nichodemus O Onwubiko; Angela Borst; Suraya A Diaz; Katharina Passkowski; Felicia Scheffel; Ingrid Tessmer; Heinz P Nasheuer
Journal:  Nucleic Acids Res       Date:  2020-04-17       Impact factor: 16.971

View more
  1 in total

1.  SV40 T antigen helicase domain regions responsible for oligomerisation regulate Okazaki fragment synthesis initiation.

Authors:  Nichodemus O Onwubiko; Felicia Scheffel; Ingrid Tessmer; Heinz Peter Nasheuer
Journal:  FEBS Open Bio       Date:  2022-02-07       Impact factor: 2.693

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.